maleimidomethyl) cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

19. The composition according to any one of claims 13 to 18, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein D is selected from the group consisting of auristatin, dolostantin, DM1, DM3, DM4, MMAE and MMAF.

20. The composition according to any one of claims 13 to 19, wherein the CD79b antibody-drug conjugate is anti-CD79b-MC-vc-PAB-MMAE.

21. The composition according to any one of claims 13 to 20, wherein the anti-CD79b antibody in said CD79b antibody-drug conjugate is huMA79b.v28.

~~22. A method of treatment of patient suffering from cancer by administering an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, in combination with a CD79b antibody-drug conjugate, to a patient in the need of such treatment.~~

~~23. The method according to claim 22, characterized in that said cancer is a CD20 expressing cancer.~~

~~24. The method according to claims 22 to 23 characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.~~

~~25. The method according to claims 22 to 24, characterized in that said anti-CD20 antibody is a humanized B-Ly1 antibody.~~

~~26. The method according to any one of claims 22 to 25, characterized in that said anti-CD20 antibody is obinutuzumab.~~

~~27. The method according to any one of claims 22 to 26, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.~~

~~28. The method according to any one of claims 22 to 27, characterized in that said CD79b antibody in the CD79b antibody-drug conjugate comprises at least one, two, three, four, five or six HVRs selected from the group consisting of:~~

(i) HVR-L1 comprising sequence A1-A15, wherein A1-A15 is KASQSVDYDGDSFLN (SEQ ID NO: 131);

(ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is AASNLES (SEQ ID NO: 132);

(iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQSNEDPLT (SEQ ID NO: 133);

(iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GYTFSSYWIE (SEQ ID NO: 134);

(v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GEILPGGGDTNYNEIFKG (SEQ ID NO: 135) and

(vi) HVR-H3 comprising sequence F1-F10, wherein F1-F10 IS TRRVPVYFDY (SEQ ID NO: 136).

29. The method according to any one of claims 22 to 28, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein

(a) Ab is the CD79b antibody of claim 28;

(b) L is a linker;

(c) D is a drug moiety.

30. The method according to any one of claims 22 to 29, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein L is selected from 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

31. The method according to any one of claims 22 to 30, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein D is selected from the group consisting of auristatin, dolostantin, DM1, DM3, DM4, MMAE and MMAF.

32. The method according to any one of claims 22 to 31, wherein the CD79b antibody-drug conjugate is anti-CD79b-MC-vc-PAB-MMAE.

~~33. The method according to any one of claims 22 to 32, wherein the anti-CD79b antibody in said CD79b antibody-drug conjugate is huMA79b.v28.~~

~~34.~~22. Use of an afucosylated anti-CD20 antibody with an amount of fucose of 60% or less of the total amount of oligosaccharides (sugars) at Asn297, for the manufacture of a medicament for the treatment of cancer in combination with a CD79b antibody-drug conjugate.

~~35.~~23. The use according to claim ~~34~~22, characterized in that said cancer is a CD20 expressing cancer.

~~36.~~24. The use according to claims ~~34~~–22 or ~~35~~23, characterized in that said CD20 expressing cancer is a lymphoma or lymphocytic leukemia.

~~37.~~25. The use according to any one of claims ~~34~~-22 to ~~36~~24, characterized in that said anti-CD20 antibody is a humanized B-Ly1 antibody.

~~38.~~26. The use according to any one of claims ~~34~~-22 to ~~37~~25, characterized in that said anti-CD20 antibody is obinutuzumab.

~~39.~~27. The use according to any one of claims ~~34~~-22 to ~~38~~26, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.

~~40.~~28. The use according to any one of claims ~~34~~–22 to ~~39~~27, characterized in that said CD79b antibody in the CD79b antibody-drug conjugate comprises at least one, two, three, four, five or six HVRs selected from the group consisting of:

(i) HVR-L1 comprising sequence A1-A15, wherein A1-A15 is KASQSVDYDGDSFLN (SEQ ID NO: 131);

(ii) HVR-L2 comprising sequence B1-B7, wherein B1-B7 is AASNLES (SEQ ID NO: 132);

(iii) HVR-L3 comprising sequence C1-C9, wherein C1-C9 is QQSNEDPLT (SEQ ID NO: 133);

(iv) HVR-H1 comprising sequence D1-D10, wherein D1-D10 is GYTFSSYWIE (SEQ ID NO: 134);

(v) HVR-H2 comprising sequence E1-E18, wherein E1-E18 is GEILPGGGDTNYNEIFKG (SEQ ID NO: 135) and

(vi) HVR-H3 comprising sequence F1-F10, wherein F1-F10 IS TRRVPVYFDY (SEQ ID NO: 136).

~~41.~~29. The use according to any one of claims ~~34–~~22 to ~~40~~28, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein

(a) Ab is the CD79b antibody of claim ~~40~~28;

(b) L is a linker;

(c) D is a drug moiety.

~~42.~~30. The use according to any one of claims ~~34–~~22 to ~~41~~29, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein L is selected from 6-maleimidocaproyl (MC), maleimidopropanoyl (MP), valine-citrulline (val-cit), alanine-phenylalanine (ala-phe), p-aminobenzyloxycarbonyl (PAB), N-Succinimidyl 4-(2-pyridylthio) pentanoate (SPP), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (SMCC), and N-Succinimidyl (4-iodo-acetyl) aminobenzoate (SIAB).

~~43.~~31. The use according to any one of claims ~~34–~~22 to ~~42~~30, the CD79b antibody-drug conjugate having the formula Ab-(L-D)p, wherein D is selected from the group consisting of auristatin, dolostantin, DM1, DM3, DM4, MMAE and MMAF.

~~44.~~32. The use according to any one of claims ~~34–~~22 to ~~43~~31, wherein the CD79b antibody-drug conjugate is anti-CD79b-MC-vc-PAB-MMAE.

~~45.~~33. The use according to any one of claims ~~34–~~22 to ~~44~~32, wherein the anti-CD79b antibody in said CD79b antibody-drug conjugate is huMA79b.v28.

~~46.~~34. The use according to any one of claims ~~34–~~22 to ~~45~~33, characterized in that one or more additional other cytotoxic, chemotherapeutic or anti-cancer agents, or compounds or ionizing radiation that enhance the effects of such agents are administered.